Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis.


Journal

Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185

Informations de publication

Date de publication:
02 2019
Historique:
pubmed: 3 11 2017
medline: 18 12 2019
entrez: 3 11 2017
Statut: ppublish

Résumé

Peripapillary retinal nerve fibre layer (pRNFL) thickness is emerging as a marker of axonal degeneration in multiple sclerosis (MS). We aimed to prospectively assess the predictive value of pRNFL for progression of physical and cognitive disability in relapsing-remitting MS (RRMS). In this 3-year longitudinal study on 151 RRMS patients, pRNFL was measured by spectral-domain optical coherence tomography (OCT). We used proportional hazard models, correcting for age, sex, disease duration, Expanded Disability Status Scale (EDSS) and Symbol Digit Modalities Test (SDMT) at baseline, to test a pRNFL thickness ≤88 µm at baseline for prediction of EDSS progression and cognitive decline. We also evaluated the decrease in pRNFL thickness from baseline to year 3 in a multivariate linear regression model. pRNFL thickness ≤88 µm was independently associated with a threefold increased risk of EDSS progression ( p < 0.001) and a 2.7-fold increased risk of cognitive decline within the subsequent 3 years ( p < 0.001). Mean pRNFL delta was -5.3 µm (SD, 4.2). It was significantly negatively impacted by EDSS progression, cognitive decline, higher age and disease duration, while positively impacted by disease-modifying therapy (DMT). Cross-sectional and longitudinal monitoring of pRNFL is useful as a biomarker for prediction of physical and cognitive disability progression in patients with RRMS in everyday clinical practice.

Sections du résumé

BACKGROUND
Peripapillary retinal nerve fibre layer (pRNFL) thickness is emerging as a marker of axonal degeneration in multiple sclerosis (MS).
OBJECTIVE
We aimed to prospectively assess the predictive value of pRNFL for progression of physical and cognitive disability in relapsing-remitting MS (RRMS).
METHODS
In this 3-year longitudinal study on 151 RRMS patients, pRNFL was measured by spectral-domain optical coherence tomography (OCT). We used proportional hazard models, correcting for age, sex, disease duration, Expanded Disability Status Scale (EDSS) and Symbol Digit Modalities Test (SDMT) at baseline, to test a pRNFL thickness ≤88 µm at baseline for prediction of EDSS progression and cognitive decline. We also evaluated the decrease in pRNFL thickness from baseline to year 3 in a multivariate linear regression model.
RESULTS
pRNFL thickness ≤88 µm was independently associated with a threefold increased risk of EDSS progression ( p < 0.001) and a 2.7-fold increased risk of cognitive decline within the subsequent 3 years ( p < 0.001). Mean pRNFL delta was -5.3 µm (SD, 4.2). It was significantly negatively impacted by EDSS progression, cognitive decline, higher age and disease duration, while positively impacted by disease-modifying therapy (DMT).
CONCLUSION
Cross-sectional and longitudinal monitoring of pRNFL is useful as a biomarker for prediction of physical and cognitive disability progression in patients with RRMS in everyday clinical practice.

Identifiants

pubmed: 29095097
doi: 10.1177/1352458517740216
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

196-203

Auteurs

Gabriel Bsteh (G)

Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Harald Hegen (H)

Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Barbara Teuchner (B)

Department of Ophthalmology, Medical University of Innsbruck, Innsbruck, Austria.

Matthias Amprosi (M)

Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Klaus Berek (K)

Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Felix Ladstätter (F)

Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Sebastian Wurth (S)

Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Michael Auer (M)

Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Franziska Di Pauli (F)

Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Florian Deisenhammer (F)

Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Thomas Berger (T)

Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH